G92.00
Immune effector cell-associated neurotoxicity syndrome, grade unspecified
Clinical Classification Guidelines
Inclusion Terms
- ICANS, grade unspecified
Medical Intelligence & Overview
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological complication that can occur after certain types of immunotherapy treatments, particularly those involving immune effector cells like CAR T-cell therapy. When the severity of this condition isn't specifically graded, it is classified as grade unspecified. This condition may involve symptoms ranging from mild confusion to severe neurological impairments, necessitating careful monitoring and management. Understanding the causes, symptoms, diagnosis, and potential treatment options can help patients and caregivers better navigate this complex complication.
Causes & Symptoms
Clinical Causes: Use of immune effector cell therapies such as CAR T-cell therapy Activation and proliferation of immune cells attacking cancer cells, which can also affect the nervous system Release of inflammatory substances, leading to neuroinflammation Pre-existing neurological conditions that may increase risk Underlying infections or metabolic disturbances that can compound neurological symptoms
Key Symptoms: Altered mental status, including confusion or disorientation Speech difficulties or aphasia Seizures Afferent or efferent pupil abnormalities Motor weakness or paralysis Somnolence or decreased consciousness Focal neurological deficits with localized weakness or sensory loss In severe cases, coma
Diagnostic & Treatment
Diagnosis Path: Neurological examination to identify deficits Electroencephalogram (EEG) to detect seizure activity Brain imaging studies like MRI or CT scans to rule out other causes Laboratory tests to identify infections or metabolic issues Assessment of recent immunotherapy treatments and timing of symptom onset
Treatment Protocols: Corticosteroids to reduce brain inflammation Anti-seizure medications if seizures are present Monitoring in an intensive care setting for severe cases Fluid management to address cerebral edema Discontinuation or modification of immunotherapy if symptoms worsen Addressing underlying metabolic or infectious conditions that may contribute Rehabilitation therapies to support neurological recovery
Clinical Advice & FAQs
Billing Guidance
Is G92.00 a billable ICD-10 code?
Yes, G92.00 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G92.00?
Clinical documentation must specify the nature of Immune effector cell-associated neurotoxicity syndrome, grade unspecified and any associated comorbidities for accurate reporting.
Cite this Clinical Reference